Adagene Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filerEmerging growth company
State of Incorporation
Cayman Islands
Business Address
4F, BUILDING C14, NO. 218, XINGHU STREET, JIANGSU, F4, 00000
Mailing Address
4F, BUILDING C14, NO. 218, XINGHU STREET, JIANGSU, F4, 00000
Phone
86-512-87773632
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$17.61M
Net Income
$38.74M
Total Liabilities
$-0.30
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | April 1, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
April 1, 2026
- Proprietary 'smart' antibody platforms (SAFEbodies, NEObodies, POWERbodies) designed to improve cancer treatment safety and efficacy.
- Strategic partnerships with industry leaders like Sanofi and Exelixis provide non-dilutive capital and validation.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.